Related Experiment Videos
Tylophora compounds as Na+/K(+)-ATPase inhibitors
J N Gnabre1, J L Pinnas, R B Bates
1Health Sciences Center, University of Arizona, Tucson, AZ 85724.
General Pharmacology
|September 1, 1993
Summary
Acetyltylophoroside and tylogenin inhibit the Na+/K(+)-ATPase enzyme, despite their distinct structures compared to cardiac glycosides. A computational model explains how these diverse molecules interact with the Na+/K(+)-ATPase receptor.
Area of Science:
- Biochemistry
- Pharmacology
- Structural Biology
Background:
- The Na+/K(+)-ATPase enzyme is a critical target for various therapeutic agents, including cardiac glycosides.
- Acetyltylophoroside (AcT) and tylogenin are compounds with structures significantly different from cardiac glycosides.
- Despite structural dissimilarities, AcT and tylogenin have been observed to inhibit Na+/K(+)-ATPase activity.
Purpose of the Study:
- To investigate the mechanism by which structurally diverse compounds like AcT and tylogenin interact with and inhibit the Na+/K(+)-ATPase.
- To develop a molecular model explaining the binding of different classes of Na+/K(+)-ATPase inhibitors to their receptor.
Main Methods:
- Computational calculation of the lowest energy conformations for AcT and tylogenin.
- Superposition analysis comparing the calculated conformations of AcT and tylogenin with X-ray crystal structures of cardiac glycosides and chlormadinone acetate.
Main Results:
- The study identified key conformational similarities and differences between AcT, tylogenin, and known cardiac glycosides.
- A molecular model was proposed based on the superposition analysis, illustrating the potential binding interactions of these diverse inhibitors with the Na+/K(+)-ATPase receptor.
Conclusions:
- The findings suggest that compounds with varying structures can effectively inhibit Na+/K(+)-ATPase by interacting with a conserved binding site.
- The developed model provides insights into the structure-activity relationships of Na+/K(+)-ATPase inhibitors and can guide the design of new therapeutic agents targeting this enzyme.